News | October 13, 2021
PCI Pharma Services acquires LSNE for its CDMO business
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Since its inception, the company has either acquired or taken a majority stake in five companies
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Subscribe To Our Newsletter & Stay Updated
